<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586972</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A03160-57</org_study_id>
    <nct_id>NCT04586972</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (&gt; 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;</brief_title>
  <acronym>SOFIA</acronym>
  <official_title>Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (&gt; 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gérond'if</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gérond'if</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to realize an observational &quot;real life&quot; study conducted&#xD;
      in French geriatric settings, to assess safety and efficacy in ≥ 80 year-old patients with&#xD;
      nonvalvular Atrial fibrillation (AF) newly treated with Apixaban.&#xD;
&#xD;
      Moreover, in this geriatric population the adequacy of Apixaban dosage and events (bleeding&#xD;
      and stroke) will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a muliticentric, observational, prospective study.&#xD;
&#xD;
      This study will be conducted in about 40 geriatric settings in France.&#xD;
&#xD;
      The planned duration of the inclusion period is 18 months in each center.&#xD;
&#xD;
      The follow-up period starts one year after inclusion with phone contact or unscheduled visit&#xD;
      at 3, 6, 9 and 12 months.&#xD;
&#xD;
      During this follow-up, participants physicians will record patients' data during visit&#xD;
      directly from the patients or their physicians or their families and by phone.&#xD;
&#xD;
      The following data will be colllected:&#xD;
&#xD;
        -  At M0 : Socio-demographics, clinical and biological data; embolic risk and emorrhagic&#xD;
           risk scores,cognitive function, number of falls, blood pressure, nutritional assessment,&#xD;
           athonomy, comorbidities, data on anticoagulant therapy, treatment discontinuation and&#xD;
           clinical evaluation.&#xD;
&#xD;
        -  At M3, M6, M9 and M12: • Number of falls, all treatment schedule, record of major&#xD;
           bleeding events, record of any other bleeding events, record of other serious events,&#xD;
           record of other non-major events, treatment discontinuation, and social and medical&#xD;
           environment.&#xD;
&#xD;
        -  Only M6 and M12: Renal function (both Cockcroft-Gault, chronic Kidney Disease,&#xD;
           epidemiology Collaboration &quot;CKD EPI&quot; and the four variable modification of Diet in renal&#xD;
           Disease equation &quot;MDRD&quot;)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Assessment of the incidence of bleeding events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine bleeding risk according (ATRIA bleeding) score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of compliance with treatment by (Apixaban) according (Morisky) Score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To quantifie risk of hemorrhage according (HEMORR₂HAGES) Score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the risk of bleeding according the (HAS-BLED) Score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">808</enrollment>
  <condition>Nonvalvular Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients newly treated with Apixaban for non-valvular atrial fibrillation (no mechanical&#xD;
        heart valves, no known moderate or severe mitral stenosis)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 80 years and older.&#xD;
&#xD;
          -  Patients with non-valvular atrial fibrillation (documented on electrocardiography or&#xD;
             other medical evidence like medical chart, hospital discharge note, physician's letter&#xD;
             within 3 years before enrollment).&#xD;
&#xD;
          -  Followed in geriatric settings (office consultation, acute care, rehabilitation&#xD;
             settings and nursing homes).&#xD;
&#xD;
          -  Newly treated (less than 6 months) with Apixaban (5mg twice daily (or 2.5 mg twice&#xD;
             daily for patients with 2 of the following criteria : age &gt; 80 years, creatinine &gt; 133&#xD;
             μmol/l, weight &lt; 60 kg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusing to participate.&#xD;
&#xD;
          -  Participation to a clinical trial.&#xD;
&#xD;
          -  Contraindication to use of Apixaban as described in the Summary of Product&#xD;
             Characteristics .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Hanon, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Geriatric Department, Broca hospital,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Dufour</last_name>
    <phone>+33 (0) 185781011</phone>
    <email>isabelle.dufour@gerondif.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margot Bobin</last_name>
    <phone>+33 (0) 185781010</phone>
    <email>margot.bobin@gerondif.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Geriatric Department, Broca Hospital</name>
      <address>
        <city>Paris</city>
        <state>IIe-de-France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Hanon, MD PhD</last_name>
      <phone>+33 (0)1 44 08 35 03,</phone>
      <email>olivier.hanon@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonvalvular Atrial fibrillation</keyword>
  <keyword>Apixaban.</keyword>
  <keyword>Bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

